Quarter Period Consolidated Statement Of Income

Oncolys BioPharma Inc. - Filing #7611807

Concept 2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
Quarter period consolidated statement of income
Statement of income
Net sales
642,494,000 JPY
314,179,000 JPY
Gross profit (loss)
198,803,000 JPY
236,113,000 JPY
Selling, general and administrative expenses
Remuneration for directors (and other officers)
174,159,000 JPY
348,523,000 JPY
Taxes and dues
101,945,000 JPY
81,221,000 JPY
Selling, general and administrative expenses
1,653,357,000 JPY
1,910,766,000 JPY
Operating profit (loss)
-1,454,554,000 JPY
-1,674,652,000 JPY
Non-operating income
Interest income
494,000 JPY
565,000 JPY
Dividend income
3,000 JPY
3,000 JPY
Non-operating income
38,643,000 JPY
568,000 JPY
Non-operating expenses
Interest expenses
4,169,000 JPY
4,170,000 JPY
Non-operating expenses
84,977,000 JPY
49,453,000 JPY
Ordinary profit (loss)
-1,500,888,000 JPY
-1,723,537,000 JPY
Extraordinary losses
Impairment losses
19,845,000 JPY
11,140,000 JPY
Extraordinary losses
110,825,000 JPY
367,821,000 JPY
Profit (loss) before income taxes
-1,611,714,000 JPY
-2,091,359,000 JPY
Income taxes - current
3,725,000 JPY
3,727,000 JPY
Income taxes
3,725,000 JPY
3,727,000 JPY
Profit (loss)
-1,615,439,000 JPY
-1,615,439,000 JPY
-1,615,439,000 JPY
-1,615,439,000 JPY
-2,095,087,000 JPY
-2,095,087,000 JPY
-2,095,087,000 JPY
-2,095,087,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.